Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.49 |
| ▸ | TEK | Q02763 | 3/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.45 |
| ▸ | GCGR | P47871 | 4/20 | 0.45 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69075 | 0.92 | MAPK14 (0.49) | MAPK14CSNK1DCSNK1ETEKMAPK13 | |
| SCHEMBL66928 | 0.88 | TEK (0.60) | MAPK14CSNK1DCSNK1ETEKMAPK13 | |
| SCHEMBL67174 | 0.86 | MAPK14 (0.50) | MAPK14CSNK1DCSNK1ETEKMAPK13 | |
| SCHEMBL68402 | 0.86 | SMPD3 (0.57) | MAPK14CSNK1DCSNK1ETEKMAPK13 | |
| SCHEMBL67554 | 0.86 | TEK (0.46) | MAPK14CSNK1DCSNK1ETEKMAPK13 | |
| SCHEMBL68844 | 0.85 | MAPK14 (0.48) | MAPK14CSNK1DCSNK1ETEKMAPK13 | |
| SCHEMBL68107 | 0.85 | ALOX5 (0.49) | MAPK14CSNK1DCSNK1ETEKMAPK13 | |
| SCHEMBL67571 | 0.85 | MAPK13 (0.50) | MAPK14CSNK1DTEKMAPK13MAPK12 | |
| SCHEMBL67374 | 0.85 | MAPK14 (0.44) | MAPK14CSNK1DCSNK1ETEKMAPK13 | |
| SCHEMBL67834 | 0.83 | TEK (0.47) | MAPK14CSNK1DCSNK1ETEKMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | MAPK14 484/4885CSNK1D 1506/4885CSNK1E 1110/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | MAPK14 218/4885CSNK1D 835/4885CSNK1E 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.